AstraZeneca PLC
Change company Symbol lookup
Select an option...
AZN AstraZeneca PLC
ALLE Allegion PLC
INTU Intuit Inc
TSLA Tesla Inc
TWLO Twilio Inc
JHS John Hancock Income Securities Trust
AMRC Ameresco Inc
ET Energy Transfer LP
AHCO Adapthealth Corp
LPSN LivePerson Inc
Go

Health Care : Pharmaceuticals | Large Cap Blend
Based in United Kingdom
Company profile

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Premarket

Last Trade
Delayed
$54.41
-0.38 (-0.69%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$54.79
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
22,026

10-day average volume:
5,574,523
22,026

SESN, GNRC & PYPL Class Actions and Lead Plaintiff Deadlines - Bronstein, Gewirtz & Grossman, LLC

11:00 am ET October 11, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 11, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Image: https://www.accesswire.com/users/newswire/images/663842/BRONSTEIN-LOGO082120.jpg

Sesen Bio, Inc. (NASDAQ:SESN)

Class Period: December 21, 2020 - August 17, 2021

Deadline: October 18, 2021

For more info:www.bgandg.com/sesn.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose: (1) that Sesen Bio's clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) that three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum; (4) that Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) that, as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Generac Holdings Inc. (NYSE:GNRC)

Class Period: February 23, 2021 - July 29, 2021

Deadline: October 19, 2021

For more info:www.bgandg.com/gnrc.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Generac's portable generators posed an unreasonable risk of injury to users and the public; (2) as a result, at least seven finger amputations and one crushed finger had been reported to the Company; (3) as a result, Generac would face increased regulatory scrutiny; (4) the Company would end sales in its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada in June 2021; (5) the Company would recall its Generac® and DR® 6500 Watt and 8000 Watt portable generators in the United States and Canada; (6) the end of sales and the recall would occur before the Company's noted hurricane and wildfire seasons and following the Texas outage-periods the Company has touted for sales; and (7) as a result, defendants' public statements and statements to journalists were materially false and/or misleading at all relevant times.

PayPal Holdings, Inc. (NASDAQ:PYPL)

Class Period: February 9, 2017 - July 28, 2021

Deadline: October 19, 2021

For more info:www.bgandg.com/pypl.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PayPal had deficient disclosure controls and procedures; (2) as a result, PayPal's business practices with respect to PayPal Credit remained non-compliant with applicable laws and/or regulations; (3) PayPal's practices regarding payment of interchange rates related to its debit cards were likewise non-compliant with applicable laws and/or regulations; (4) accordingly, PayPal's revenues derived from its PayPal Credit and debit card practices were in part the subject of improper conduct and thus unsustainable; (5) all the foregoing subjected the Company to an increased risk of regulatory investigation and enforcement; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times.

CONTACT:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Nathanson

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

View source version on accesswire.com:

https://www.accesswire.com/663842/SESN-GNRC-PYPL-Class-Actions-and-Lead-Plaintiff-Deadlines--Bronstein-Gewirtz-Grossman-LLC

comtex tracking

COMTEX_394951213/2457/2021-10-11T11:00:15

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.